Ocular Disease: Novel Results Announced By This Biotech Company

LianBio Announces Groundbreaking Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis.

LianBio, a leading biopharmaceutical company, has recently announced the topline results from their Phase 3 LIBRA trial of TP-03, a novel investigational therapy, in Chinese patients diagnosed with Demodex blepharitis. The results have shown significant efficacy of TP-03, marking a significant step forward in the fight against this debilitating ocular d…